keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasys

keyword
https://www.readbyqxmd.com/read/28092253/-mexican-treatment-goals-for-plaque-psoriasis
#1
Lorena Estrada-Aguilar, Mario Amaya-Guerra, Minerva Gómez-Flores, Esther Guevara-Sanginés, Fermín Jurado-Santacruz, Adriana Lopeztello-Santillán, César Maldonado-García, Mónica Rivera-Gómez, Norma Rodríguez-Martínez, Luis Vega-González
Psoriasis is a chronic inflammatory disease with a worldwide prevalence between 6 and 39% in moderate to severe forms. In European countries like Germany and England was identified that only one third of patients with moderate to severe forms will receive systemic management, this fact motivated to integrate into Europe an international consensus on treatment goals with the aim of providing support to the dermatologist by algorithms that serve as a therapeutic guide that allows you to gain control short and long term effects of this disease...
January 2017: Revista Médica del Instituto Mexicano del Seguro Social
https://www.readbyqxmd.com/read/28092212/systemic-medications-used-in-treatment-of-common-dermatological-conditions-safety-profile-with-respect-to-pregnancy-breast-feeding-and-content-in-seminal-fluid
#2
S M Brown, K A Aljefri, R Waas, P J Hampton
: Prescribing for pregnant or lactating patients and male patients wishing to father children can be a difficult area for dermatologists. There is a lack of review articles of commonly used systemic medications in dermatology with respect to their effects on developing embryogenesis and their potential transfer across the placenta, in breast milk and in seminal fluid. This paper aims to provide an up to date summary of evidence to better equip dermatologists to inform patients about the effects of systemic medications commonly used in dermatology to treat conditions such as atopic dermatitis, psoriasis and acne, on current and future embryogenesis and fertility...
January 16, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28088907/tofacitinib-an-oral-janus-kinase-inhibitor-perspectives-in-dermatology
#3
Kresimir Kostovic, Sandra Jerkovic Gulin, Zrinka Bukvic Mokos, Romana Ceovic
BACKGROUND: Tofacitinib (formerly known as CP-690,550, CP690550, tasocitinib), a novel selective immunosuppressant, is a small molecule classified as Janus kinase inhibitor. The aim of this review article is to present updated data summary on the tofacitinib in the field of dermatology. METHOD: We undertook a structured search of bibliographic databases for peer-reviewed scientific articles, including review articles, original research articles as well as case report articles based on inclusion/exclusion criteria...
January 12, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28087133/secukinumab-sustains-early-patient-reported-outcome-benefits-through-1%C3%A2-year-results-from-2-phase-iii-randomized-placebo-controlled-clinical-trials-comparing-secukinumab-with-etanercept
#4
Bruce Strober, Alice B Gottlieb, Bintu Sherif, Patrick Mollon, Isabelle Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, Charis Papavassilis, Mark G Lebwohl
BACKGROUND: Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment. OBJECTIVE: This analysis focused on the effect of secukinumab treatment on patient-reported health-related quality of life as assessed by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis. METHODS: The proportion of subjects achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response, and sustained DLQI score 0/1 response up to week 52 were compared between secukinumab and etanercept...
January 10, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28079929/the-impact-of-age-on-psoriasis-health-care-in-germany
#5
A Trettel, C Spehr, A Körber, M Augustin
INTRODUCTION: Inequality between age groups has been demonstrated in the prescription of biologics, yet systematic real-world data about age-related differences in psoriasis care are missing. OBJECTIVE: To investigate disparities in psoriasis characteristics by age groups and to identify potential impact on psoriasis health care. PATIENTS AND METHODS: Data analysis included 3,615 patients from the German Psoriasis registry PsoBest, which observes adult patients with moderate to severe psoriasis or psoriatic arthritis (PsA) on systemic treatment over a time period of 10 years...
January 12, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28078672/determinants-for-drug-survival-of-methotrexate-in-patients-with-psoriasis-split-for-different-reasons-of-discontinuation-results-of-the-prospective-mtx-capture
#6
M Otero, J van den Reek, M Seyger, P Van Der Kerkhof, W Kievit, E de Jong
BACKGROUND: Methotrexate is a widely used treatment for psoriasis. It is important to gain insight into the reasons for discontinuation of methotrexate and determinants for drug survival. OBJECTIVES: To describe 5-year drug survival for methotrexate in patients with psoriasis split for different reasons of discontinuation, and to identify determinants for drug survival. METHODS: Data were extracted from a prospective psoriasis registry of patients treated with methotrexate (MTX-CAPTURE)...
January 12, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28078206/infectious-atopic-and-inflammatory-diseases-childhood-adversities-and-familial-aggregation-are-independently-associated-with-the-risk-for-mental-disorders-results-from-a-large-swiss-epidemiological-study
#7
Vladeta Ajdacic-Gross, Aleksandra Aleksandrowicz, Stephanie Rodgers, Margot Mutsch, Anja Tesic, Mario Müller, Wolfram Kawohl, Wulf Rössler, Erich Seifritz, Enrique Castelao, Marie-Pierre F Strippoli, Caroline Vandeleur, Roland von Känel, Rosa Paolicelli, Markus A Landolt, Cornelia Witthauer, Roselind Lieb, Martin Preisig
AIM: To examine the associations between mental disorders and infectious, atopic, inflammatory diseases while adjusting for other risk factors. METHODS: We used data from PsyCoLaus, a large Swiss Population Cohort Study (n = 3720; age range 35-66). Lifetime diagnoses of mental disorders were grouped into the following categories: Neurodevelopmental, anxiety (early and late onset), mood and substance disorders. They were regressed on infectious, atopic and other inflammatory diseases adjusting for sex, educational level, familial aggregation, childhood adversities and traumatic experiences in childhood...
December 22, 2016: World Journal of Psychiatry
https://www.readbyqxmd.com/read/28077577/extracellular-microrna-signature-of-human-helper-t-cell-subsets-in-health-and-autoimmunity
#8
Anna Torri, Donatella Carpi, Elisabetta Bulgheroni, Maria-Cristina Crosti, Monica Moro, Paola Gruarin, Riccardo L Rossi, Grazisa Rossetti, Dolores Di Vizio, Mirjam Hoxha, Valentina Bollati, Cristina Gagliani, Carlo Tacchetti, Moira Paroni, Jens Geginat, Laura Corti, Luigia Venegoni, Emilio Berti, Massimiliano Pagani, Giuseppe Matarese, Sergio Abrignani, Paola de Candia
Upon TCR stimulation, CD4+ T lymphocytes release extracellular vesicles (EVs) containing microRNAs. However, no data are available on whether human CD4+ T cell subsets release EVs containing different pattern of microRNAs. The present work aimed at filling this gap by assessing the microRNA content in EVs released upon in vitro TCR stimulation of Th1, Th17 and T regulatory (Treg) cells. Our results indicate that EVs released by Treg cells are significantly different compared to those released by the other subsets...
January 11, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28076860/efficacy-and-survival-of-systemic-psoriasis-treatments-an-analysis-of-the-swiss-registry-sdntt
#9
Julia-Tatjana Maul, Vahid Djamei, Antonios G A Kolios, Barbara Meier, Justine Czernielewski, Pascal Jungo, Nikhil Yawalkar, Carlo Mainetti, Emmanuel Laffitte, Christina Spehr, Mark Anliker, Markus Streit, Matthias Augustin, Stephan Rustenbach, Curdin Conrad, Jürg Hafner, Wolf-Henning Boehncke, Luca Borradori, Michel Gilliet, Peter Itin, Lars E French, Peter Häusermann, Alexander A Navarini
BACKGROUND: The Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapies) records the long-term safety and effectiveness of systemic treatment regimens for psoriasis. PATIENTS AND METHODS: Patients with moderate to severe psoriasis are included in the SDNTT when treatment with a conventional systemic agent or biologic is initiated that was not previously used by the respective patient. Patients are followed over a 5-year period. Clinical data are obtained every 3-6 months using standardized case report forms...
January 12, 2017: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/28074446/efficacy-and-safety-of-switching-to-ixekizumab-in-etanercept-non-responders-a-subanalysis-from-two-phase-iii-randomized-clinical-trials-in-moderate-to-severe-plaque-psoriasis-uncover-2-and-3
#10
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Luis Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin
BACKGROUND: Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. OBJECTIVE: Our aim was to assess the response to ixekizumab in patients with moderate-to-severe plaque psoriasis who did not respond adequately to etanercept using a post-hoc analysis in two phase III studies. METHODS: For the subanalyses in two phase III trials (UNCOVER-2 and -3), non-response was defined by either failure to have a static physician global assessment (sPGA) of 0/1 in UNCOVER-2 or failure to have at least 75% improvement in psoriasis area and severity index (PASI 75) in UNCOVER-3 at Week 12 of each study...
January 10, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28074414/spontaneous-remission-of-subcutaneous-scedosporiosis-caused-by-scedosporium-dehoogii-in-a-psoriatic-patient
#11
Fang-Gu Li, Yan-Ping Yang, Wei Li, Ping Sheng, Wen Li, Wen-Ming Huang, Yi-Ming Fan
To date, only one case of post-traumatic endophthalmitis caused by Scedosporium dehoogii has been reported, but its contamination or colonization might not be precluded due to the absence of pathogenic isolation and/or pathological examination. We report the first case to our knowledge of S. dehoogii-induced subcutaneous scedosporiosis in a psoriatic patient. A 58-year-old man with 5-year history of psoriasis vulgaris and immunosuppressant therapy developed pyrexia and multiple subcutaneous abscesses on both knees...
January 10, 2017: Mycopathologia
https://www.readbyqxmd.com/read/28071837/use-of-tnf-inhibitors-and-ustekinumab-for-psoriasis-during-pregnancy-a-patient-series
#12
Tamara Lund, Simon Francis Thomsen
From 2002 to 2016 a total of seven women with severe refractory psoriasis were exposed to the TNF-inhibitors infliximab and adalimumab or to the IL12/23 inhibitor ustekinumab during one or more pregnancies. Maternal, fetal or teratogenic toxicity were not detected during pregnancy and puerperium. All pregnancies were uneventful and resulted in delivery of 10 healthy children in total, one of the women is due February 2017. Postpartum, five of the women were lactating, but none of the women or newborns developed adverse reactions...
January 10, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28069913/anti-tnf%C3%AE-antibody-induced-psoriasiform-skin-lesions-in-patients-with-inflammatory-bowel-disease-an-irish-cohort-study
#13
S Kirthi, A-M Tobin, M Hussey, F Scaldaferri, D McNamara
AIM: To determine the prevalence of psoriasis in an IBD cohort with reference to clinical characteristics and anti-TNFα use. METHODS: Patients with psoriasis and IBD were retrospectively identified from the IBD database at Tallaght Hospital from 2000 to 2015. Pertinent clinical data were obtained from patients notes including anti-TNFα exposure. Prevalence rates of genuine and reactive psoriasis were calculated and compared using a students T-test. A p value of < 0...
January 9, 2017: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/28069297/lesions-on-the-back-of-hands-and-female-gender-predispose-to-stigmatization-in-patients-with-psoriasis
#14
Marlena Hawro, Marcus Maurer, Karsten Weller, Romuald Maleszka, Anna Zalewska-Janowska, Andrzej Kaszuba, Zofia Gerlicz-Kowalczuk, Tomasz Hawro
BACKGROUND: Psoriasis vulgaris is characterized by disfiguring and stigmatizing skin lesions. The links among lesions distribution, severity, and stigmatization remain unclear. OBJECTIVE: We sought to investigate if the involvement of visible and sensitive areas is linked to stigmatization. METHODS: In all, 115 patients with psoriasis vulgaris were assessed for disease severity, skin lesions distribution, itch, and stigmatization using the Feelings of Stigmatization Questionnaire...
January 6, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28068891/immunological-variation-due-to-genetics-of-inflammatory-snps-and-age-and-impact-on-disease-manifestation
#15
Gary R Burleson
The immune system is a critical component in defense against viral, bacterial, parasitic, and fungal diseases. Immunological mechanisms, including immunological mediators, innate immunity, cell-mediated immunity, and humoral-mediated immunity, serve to maintain homeostasis and protect the host from disease. Immunological variation can impact defense mechanisms, however. Two factors in particular that can influence immune function are the single nucleotide polymorphisms (SNPs) and aging. SNPs affecting inflammatory cytokines are an important modifier involved in a number of diseases such as asthma, periodontal disease, atherosclerosis, diabetic retinopathy, psoriasis, and osteoporosis...
January 2017: Toxicologic Pathology
https://www.readbyqxmd.com/read/28067065/the-investigation-of-antimicrobial-peptides-expression-and-its-related-interaction-with-methotrexate-treatment-in-patients-with-psoriasis-vulgaris
#16
Emin Ozlu, Ayse Serap Karadag, Seyma Ozkanli, Serpil Oguztuzun, Ozge Akbulak, Tugba Kevser Uzuncakmak, Serkan Demirkan, Necmettin Akdeniz
BACKGROUND: Psoriasis is a chronic, inflammatory and immune-mediated disease. Recently, the role of antimicrobial peptides (AMPs) such as human beta defensins (hBDs) in the pathogenesis of psoriasis has been investigated. We aimed to evaluate the expression profiles of hBD-1 and hBD-2 in psoriatic skin before and after methotrexate (MTX) therapy and to compare healthy controls. METHODS: Immunohistochemical expressions of hBD-1 and hBD-2 were assessed in 16 patients with psoriasis vulgaris and 20 normal skin biopsies from healthy controls...
January 8, 2017: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/28065529/-comparable-infectious-risks-for-anti-tnf%C3%AE-drugs%C3%A2-and-standard-systemic-therapies-in-psoriasis
#17
J-L Schmutz
No abstract text is available yet for this article.
January 5, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28064550/the-role-of-il-4-in-psoriasis
#18
Matthias Hahn, Kamran Ghoreschi
No abstract text is available yet for this article.
January 9, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28064543/itolizumab-a-novel-anti-cd6-monoclonal-antibody-a-safe-and-efficacious-biologic-agent-for-management-of-psoriasis
#19
Sunil Dogra, Shraddha Uprety, Swaroop Hassan Suresh
Psoriasis, a chronic immune-mediated skin disorder is associated with significant physical, psychological, and quality of life impairments. Along with well-documented genetic and environmental factors, immunological factors also contribute to the pathogenesis of psoriasis. Among the immunological factors, CD6 - dependent T-cell proliferation to form Th1 and Th17 cells play a major role in the pathogenesis of psoriasis. Itolizumab is the first humanized IgG1 monoclonal antibody, which selectively targets CD6...
January 9, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28063651/recent-highlights-in-psoriasis-research
#20
REVIEW
Samuel T Hwang, Tamar Nijsten, James T Elder
This article highlights recent advances in the immunology, epidemiology, and genetics/genomics of psoriasis from 2015 through 2016. Advances sometimes generate more questions, and this article makes an attempt to point out where controversies might exist in the literature. Many of the articles mentioned were published in the Journal of Investigative Dermatology, but many articles from the broader scientific literature are also cited, to provide context and to add further validity for some of these key findings...
January 4, 2017: Journal of Investigative Dermatology
keyword
keyword
43199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"